 Mylan N.V. NASDAQ: MYL today announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of Biogens Tecfidera capsules. Dimethyl fumarate delayed release capsules 120 mg and 240 mg are indicated for the treatment of relapsing forms of multiple sclerosis MS, and are the first generic of any MS treatment in an oral solid dosage form available to patients in the U.S. 